Aberdeen Group’s Ascendis Pharma A/S ASND Stock Holding History

Aberdeen Group’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.74M	Sell	36,512 -173,642	-83%	-$40.6M	0.01%	601
2026 Q1	$48.1M	Sell	210,154 -11,523	-5%	-$2.58M	0.08%	221
2025 Q4	$47.3M	Buy	221,677 +172,251	+349%	+$35.6M	0.07%	222
2025 Q3	$9.83M	Sell	49,426 -90,180	-65%	-$16.8M	0.02%	609
2025 Q2	$24.1M	Sell	139,606 -32,125	-19%	-$5.23M	0.04%	357
2025 Q1	$26.8M	Sell	171,731 -15,449	-8%	-$2.21M	0.05%	314
2024 Q4	$25.8M	Buy	187,180 +28,967	+18%	+$3.81M	0.05%	318
2024 Q3	$23.6M	Sell	158,213 -2,389	-1%	-$323K	0.04%	351
2024 Q2	$21.9M	Buy	160,602 +21,811	+16%	+$2.97M	0.04%	362
2024 Q1	$21M	Hold	138,791	–	–	0.04%	396
2023 Q4	$17.5M	Buy	+138,791	New	+$13.8M	0.04%	421

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Aberdeen Group's ASND Position: Q2 2026 in Review

Aberdeen Group reduced its Ascendis Pharma A/S (ASND) stake by 83% in Q2 2026, selling an estimated $40.6M and leaving 36,512 shares worth $9.74M. The position accounts for 0.01% of the portfolio, ranked #601.

Aberdeen Group first reported a position in ASND in Q4 2023 and has held it in 11 quarters since. The position peaked at $48.1M in Q1 2026. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Aberdeen Group held 36,512 shares of Ascendis Pharma A/S worth $9.74M as of Q2 2026.
Aberdeen Group sold 173,642 Ascendis Pharma A/S shares in Q2 2026, an estimated $40.6M.
Ascendis Pharma A/S made up 0.01% of Aberdeen Group's portfolio in Q2 2026, its #601 holding.
Aberdeen Group first reported a position in Ascendis Pharma A/S in Q4 2023 and has held it in 11 quarters since.
Aberdeen Group's Ascendis Pharma A/S position peaked at $48.1M in Q1 2026.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.